CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-05-16 | Belldegrun Arie Director | Purchase | +1,724,137 | $2.90 | $5.0M | 1,724,137 |
| 2024-01-30 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Purchase | +190 | $3.60 | $683 | 819,590 |
| 2022-01-12 | Kazam Joshua A Director | Purchase | +15,000 | $12.60 | $189K | 258,885 |
| 2022-01-12 | Belldegrun Arie Director | Purchase | +155,039 | $12.60 | $2.0M | 195,039 |
| 2020-06-04 | Belldegrun Arie Director | Purchase | +40,000 | $47.00 | $1.9M | 40,000 |
| 2020-06-04 | Belldegrun Arie Director | Purchase | +106,382 | $47.00 | $5.0M | 1,798,163 |
Page 1 of 1 · 6 trades